As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
EASL 2019 – Alnylam lays out givosiran's benefit
Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
EASL 2019 – Having filed to float, all Cirius needs now is the data
The IPO hopeful Cirius Therapeutics presented intriguing Nash data at EASL, but with the final readout from a phase IIb study looming the company’s real value is hard to…
EASL 2019 – Intercept builds a case for Ocaliva
A look at the abstract on Intercept’s Regenerate trial seems to confirm the earlier topline result, ahead of a full data presentation later today.
EASL 2019 – Viking to push the limits of its Nash contender
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Inventiva’s fibrosis flop hits Nash hopes
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Check-Cap auditions for its screen debut
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Novo hopes slimmed-down bet can still win in obesity
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.